Usama Dar appointed as chief product and technology officer at CluePoints
Ella Day | April 2, 2025 | Appointment | Research and Development | Pharmacy, clinical trial analysis, cluepoints, pharma, research and development
CluePoints has appointed Usama Dar as its new chief product and technology officer, effective 1 April 2025. This follows Dar’s leadership and development of product and R&D teams at the company.
Dar has held leadership roles at organisations such as Westwing, Sciensus, Elsevier, The Guardian and Huawei. He has experience in eCommerce, software as a service (Saas) and artificial intelligence, and has built and led teams to develop biotech products.
Andy Cooper, chief executive officer of CluePoints, commented: “Usama is the perfect fit to support us on our journey to provide the most comprehensive, and highest quality, integrated data review platform for the clinical development industry.”
Dar stated: “What attracted me to CluePoints was its mission to harness technology to improve and accelerate clinical trials.” He added: “I look forward to applying my engineering and product expertise to streamline development and elevate CluePoints’ offerings.”
In addition to working closely with the leadership team, Dar will collaborate with CluePoints’ co-founder, Francois Torche, who will continue to develop the company’s product vision as a strategic advisor.
Established in 2012, CluePoints is a risk-based quality management (RBQM) and data quality oversight software provider. It manages risk and enhances data quality oversight in clinical trials using AI and advanced analytics.
Ella Day
2/4/2025
Related Content
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …
AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …
